Quantitative Analysis of Bone Marrow Fibrosis Highlights Heterogeneity in Myelofibrosis and Augments Histological Assessment: An Insight from a Phase II Clinical Study of Zinpentraxin Alfa

Overview

Journal Hemasphere

Publisher Wiley

Specialty Hematology

Date 2024 Jun 17

PMID 38884042

Authors

Hosuk Ryou

Korsuk Sirinukunwattana

Ruby Wood

Alan Aberdeen

Jens Rittscher

Olga K Weinberg

Robert Hasserjian

Olga Pozdnyakova

Frank Peale

Brian Higgins

Pontus Lundberg

Kerstin Trunzer

Claire N Harrison

Daniel Royston

Affiliations

Soon will be listed here.

Citing Articles

Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment.

Shi S, Ou X, Liu C, Wen H, Ke J Front Immunol. 2025; 16:1549276.

PMID: 39981236 PMC: 11839635. DOI: 10.3389/fimmu.2025.1549276.

References

Verstovsek S, Foltz L, Gupta V, Hasserjian R, Manshouri T, Mascarenhas J . Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. Haematologica. 2023; 108(10):2730-2742. PMC: 10543197. DOI: 10.3324/haematol.2022.282411. View

Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719. PMC: 9252913. DOI: 10.1038/s41375-022-01613-1. View

Kvasnicka H, Beham-Schmid C, Bob R, Dirnhofer S, Hussein K, Kreipe H . Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study. Histopathology. 2015; 68(6):905-15. DOI: 10.1111/his.12871. View

Pozdnyakova O, Rodig S, Bhandarkar S, Wu K, Thiele J, Hasserjian R . The importance of central pathology review in international trials: a comparison of local versus central bone marrow reticulin grading. Leukemia. 2014; 29(1):241-4. DOI: 10.1038/leu.2014.262. View

Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos C, Newberry K, Prijic S . Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016; 213(9):1723-40. PMC: 4995084. DOI: 10.1084/jem.20160283. View

Thiele J, Kvasnicka H, Facchetti F, Franco V, van der Walt J, Orazi A . European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005; 90(8):1128-32. View

Pilling D, Gomer R . The Development of Serum Amyloid P as a Possible Therapeutic. Front Immunol. 2018; 9:2328. PMC: 6232687. DOI: 10.3389/fimmu.2018.02328. View

Ryou H, Sirinukunwattana K, Aberdeen A, Grindstaff G, Stolz B, Byrne H . Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients. Leukemia. 2022; 37(2):348-358. PMC: 9898027. DOI: 10.1038/s41375-022-01773-0. View

Verstovsek S, Talpaz M, Wadleigh M, Isidori A, Te Boekhorst P, Savona M . A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial. Haematologica. 2024; 109(6):1977-1983. PMC: 11141656. DOI: 10.3324/haematol.2023.284410. View

10.

Pemmaraju N, Verstovsek S, Mesa R, Gupta V, Garcia J, Scandura J . Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer. 2022; 128(13):2420-2432. PMC: 9322520. DOI: 10.1002/cncr.34205. View

11.

Castano A, Lin S, Surowy T, Nowlin B, Turlapati S, Patel T . Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med. 2010; 1(5):5ra13. PMC: 2852889. DOI: 10.1126/scitranslmed.3000111. View

12.

Ryou H, Lomas O, Theissen H, Thomas E, Rittscher J, Royston D . Quantitative interpretation of bone marrow biopsies in MPN-What's the point in a molecular age?. Br J Haematol. 2023; 203(4):523-535. PMC: 10952168. DOI: 10.1111/bjh.19154. View

13.

Arber D, Orazi A, Hasserjian R, Borowitz M, Calvo K, Kvasnicka H . International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11):1200-1228. PMC: 9479031. DOI: 10.1182/blood.2022015850. View